Indication: Used as adjunctive therapy for the treatment of peptic ulcer. Also used to treat nausea and vomiting due to motion sickness.
Pharmacology: Methscopolamine is a muscarinic antagonist structurally similar to the neurotransmitter acetylcholine and acts by blocking the muscarinic acetylcholine receptors and is thus classified as an anticholinergic. Methscopolamine has many uses including the prevention of motion sickness. It is not clear how Methscopolamine prevents nausea and vomiting due to motion sickness. The vestibular part of the ear is very important for balance. When a person becomes disoriented due to motion, the vestibule sends a signal through nerves to the vomiting center in the brain, and vomiting occurs. Acetylcholine is a chemical that nerves use to transmit messages to each other. It is believe that Methscopolamine prevents communication between the nerves of the vestibule and the vomiting center in the brain by blocking the action of acetylcholine. Methscopolamine also may work directly on the vomiting center. Methscopolamine must be taken before the onset of motion sickness to be effective.
Mechanism Of Action: Methscopolamine acts by interfering with the transmission of nerve impulses by acetylcholine in the parasympathetic nervous system (specifically the vomiting center).
Drug Category: Antispasmodics; Anticholinergic Agents; ATC:A03BB03; ATC:S01FA03
Absorption: Poorly and unreliably absorbed. Total absorption is 10-25%.
Interactions:
DrugBank: Interactions for Methscopolamine
Interactions for Methscopolamine:
Methscopolamine may interact with antidepressants (tricyclic type), MAO
inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine,
amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids,
absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).
Chemical IUPAC Name: Not Available
Chemical Formula: C18H24NO4
Half Life: Not Available
Drug Type: Approved Drug
# Accession No: APRD00314
CAS Registry Number: 155-41-9
Methscopolamine News (When available)
Mylan Laboratories and Forest Laboratories Announce Nebivolol ...Jan 12, 2006 PharmaLive.com (press release), ...and maintenance treatment of major depressive disorder and for generalized anxiety disorder in adults; Namenda(R) (memantine HCl), an N- methyl-D-aspartate ...
Higher Education is meeting the challenges of FOI Act says surveyJan 8, 2006 PublicTechnology.net, The survey, a joint initiative by JISC (Joint Information Systems Committee), Universities UK and SCOP (the Standing Conference of Principals), show that the ...
How Federated Databases Benefit Bioinformatics ResearchJan 10, 2006 B-EYE-Network, ...“Find all structural homologs of putative N-acetyltransferase SR144 in B. subtillus in SCOP family Acyl-CoA N-acetyltransferase.�. ...
Universities 'coping' with freedom of information demandsJan 9, 2006 eGov monitor, The survey by the Joint Information Systems Committee, Universities UK and the Standing Conference on Principles (SCOP) was conducted to establish how the ...
Former chief scientist Shuki Gleitman joins Ascend fundJan 12, 2006 Globes, ...(Nasdaq:SCOP); an IPO by Topspin Medical Inc. (TASE:TOPMD); and Shellcase sale of its intellectual property to Tessera Technologies Inc. (Nasdaq:TSRA). ...
The North American Menopause Society Highlights from Jan/FebJan 12, 2006 PharmaLive.com (press release), In this secondary analysis of data from the UltraLow-Dose Transderm Estrogen Assessment trial (ULTRA), women who were randomized to receive either unopposed ...
Home
Copyright phasechange.org 2006.
All Rights Reserved.
